AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33548380 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenolic extra virgin olive oil (EVOO), 50 mL
Number of subjects: 20
Study 33548380 — intervention group
Group type: COMPARATOR
Intervention: Refined olive oil without polyphenols, 50 mL
Number of subjects: 20
Study 616520941 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF (co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
Number of subjects: 429
Study 616520941 — intervention group
Group type: COMPARATOR
Intervention: PI + RTV + TVD (multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF)
Number of subjects: 429
Study 36153205 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice treatment with Acapella Choice device plus vocal hygiene program
Number of subjects: 30
Study 36153205 — intervention group
Group type: COMPARATOR
Intervention: Voice treatment with Water resistance therapy plus vocal hygiene program
Number of subjects: 30
Study 35083939 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week, 30-min morning jogging intervention
Number of subjects: 0
Study 35083939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical exercise intervention)
Number of subjects: 0
Study 34337965 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (1 mg/kg, PO, q 12 h)
Number of subjects: 39
Study 34337965 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (1 mg/kg, PO, q 12 h)
Number of subjects: 39
Study 34337965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose; PO, q 12 h)
Number of subjects: 39
Study 34337965 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 39
Study 34337965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 33715054 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft alone
Number of subjects: 0
Study 33715054 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-tricalcium phosphate (β-TCP)
Number of subjects: 0
Study 33715054 — intervention group
Group type: EXPERIMENTAL
Intervention: β-TCP + autogenous bone graft 1:1
Number of subjects: 0
Study 33715054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass
Number of subjects: 0
Study 33715054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass + autogenous bone graft 1:1
Number of subjects: 0
Study 36128956 — intervention group
Group type: EXPERIMENTAL
Intervention: ACURATE neo
Number of subjects: 648
Study 36128956 — intervention group
Group type: COMPARATOR
Intervention: CoreValve Evolut
Number of subjects: 648
Study 36128956 — intervention group
Group type: EXPERIMENTAL
Intervention: New LBBB
Number of subjects: 648
Study 32548904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapulsed CO2 laser debridement (LT group)
Number of subjects: 54
Study 32548904 — intervention group
Group type: COMPARATOR
Intervention: Traditional sharp instrument/surgical debridement (RT group)
Number of subjects: 54
Study 33052809 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol box
Number of subjects: 48
Study 33052809 — intervention group
Group type: COMPARATOR
Intervention: No aerosol box
Number of subjects: 48
Study 35656881 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone EVLP
Number of subjects: 10
Study 35656881 — intervention group
Group type: COMPARATOR
Intervention: Supine EVLP
Number of subjects: 10
Study 34118980 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 29
Study 34118980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 33228614 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 592
Study 33548363 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-delivered one-on-one breast and cervical cancer screening education and navigation calls
Number of subjects: 627
Study 32423462 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) of β-lactam antibiotics (BLA)
Number of subjects: 0
Study 32423462 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion (II) of β-lactam antibiotics (BLA)
Number of subjects: 0
Study 35170739 — intervention group
Group type: EXPERIMENTAL
Intervention: SELEVER interventions (groups 1 + 2)
Number of subjects: 1054
Study 35170739 — intervention group
Group type: COMPARATOR
Intervention: SELEVER
Number of subjects: 1054
Study 32544346 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational plus implementation intentions intervention
Number of subjects: 157
Study 32544346 — intervention group
Group type: COMPARATOR
Intervention: Implementation intentions condition
Number of subjects: 157
Study 32544346 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 157
Study 32772921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 678
Study 32772921 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 678
Study 34472497 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 24
Study 34472497 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 24
Study 34472497 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (both xenon and sevoflurane)
Number of subjects: 24
Study 36302049 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit glycated haemoglobin intervention targets 5mmol/mol above current glycated haemoglobin readings
Number of subjects: 0
Study 36302049 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit glycated haemoglobin intervention targets 5mmol/mol below current glycated haemoglobin readings
Number of subjects: 0
Study 36302049 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline validated psychometric questionnaires
Number of subjects: 0
Study 36302049 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative semi-structured interviews
Number of subjects: 0
Study 32578258 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Teen Triple P Program (8 weeks)
Number of subjects: 76
Study 35657063 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Garment (CG)
Number of subjects: 75
Study 35657063 — intervention group
Group type: COMPARATOR
Intervention: Noncompression Group (NCG)
Number of subjects: 75
Study 32712762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg−1 bolus followed by 10 mcg kg−1 min−1 infusion
Number of subjects: 27
Study 32712762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg kg−1 bolus followed by 5 mcg kg−1 min−1 infusion
Number of subjects: 27
Study 32712762 — intervention group
Group type: COMPARATOR
Intervention: Control (no ketamine)
Number of subjects: 27
Study 34380099 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Number of subjects: 20
Study 34380099 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 20
Study 33236202 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 20
Study 33236202 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 20
Study 33236202 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fractional CO2 with PRP
Number of subjects: 20
Study 33236202 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fractional CO2 with NB-UVB
Number of subjects: 20
Study 33236202 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fractional CO2 with PRP and NB-UVB
Number of subjects: 20
Study 33236202 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 35082225 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dentures (CDs)
Number of subjects: 0
Study 35082225 — intervention group
Group type: COMPARATOR
Intervention: Digital dentures (DDs)
Number of subjects: 0
Study 33125282 — intervention group
Group type: EXPERIMENTAL
Intervention: Newtom‐5G
Number of subjects: 40
Study 33125282 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthophos‐SL
Number of subjects: 40
Study 33125282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranex‐3Dx (patient standing/sitting)
Number of subjects: 40
Study 33125282 — intervention group
Group type: EXPERIMENTAL
Intervention: X1
Number of subjects: 40
Study 33125282 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position with foam headrest
Number of subjects: 40
Study 33125282 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 40
Study 33125282 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred unit with supine position and foam headrest
Number of subjects: 40
Study 35693290 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 437
Study 35693290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 32702911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with electroacupuncture (EA) and computerized cognitive rehabilitation treatment (CCRT)
Number of subjects: 45
Study 32702911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with transcranial direct current stimulation (tDCS) and computerized cognitive rehabilitation treatment (CCRT)
Number of subjects: 45
Study 32702911 — intervention group
Group type: COMPARATOR
Intervention: Computerized cognitive rehabilitation treatment (CCRT) alone
Number of subjects: 45
Study 32702911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with EA and CCRT
Number of subjects: 45
Study 32702911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with tDCS and CCRT
Number of subjects: 45
Study 32702911 — intervention group
Group type: COMPARATOR
Intervention: CCRT alone
Number of subjects: 45
Study 36456003 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform (Prisma) for interdisciplinary consultation
Number of subjects: 1008
Study 33039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels ≤16 ng/mL for GDM
Number of subjects: 1763
Study 33039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels 16–26 ng/mL for GDM
Number of subjects: 1763
Study 33039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels >26 ng/mL for GDM
Number of subjects: 1763
Study 33039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels ≤15 ng/mL for preterm delivery
Number of subjects: 1763
Study 33039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels 15–21 ng/mL for preterm delivery
Number of subjects: 1763
Study 33039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels >21 ng/mL for preterm delivery
Number of subjects: 1763
Study 33039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels ≤15 ng/mL for preeclampsia
Number of subjects: 1763
Study 33039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels 15–23 ng/mL for preeclampsia
Number of subjects: 1763
Study 33039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels >23 ng/mL for preeclampsia
Number of subjects: 1763
Study 35994896 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT) containing 1 or 2 mg of estradiol and cyclical 10 mg dydrogesterone for one year
Number of subjects: 27
Study 35994896 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 27
Study 34510180 — intervention group
Group type: EXPERIMENTAL
Intervention: OWN SUPP
Number of subjects: 52
Study 34510180 — intervention group
Group type: COMPARATOR
Intervention: STER SUPP
Number of subjects: 52
Study 35618961 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor (CGF)
Number of subjects: 51
Study 35618961 — intervention group
Group type: COMPARATOR
Intervention: Collagen Membrane (CM)
Number of subjects: 51
Study 33493703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 129
Study 33493703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 33493703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and Placebo (overall population)
Number of subjects: 129
Study 33493703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and Placebo (African American women)
Number of subjects: 129
Study 33493703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and Placebo (women with lower severity of nicotine dependence)
Number of subjects: 129
Study 33493703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and Placebo (women with opioid use disorder)
Number of subjects: 129
Study 32823594 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg−1·body mass)
Number of subjects: 31
Study 32823594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 33331980 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-025 (API-in-Capsule) 800 mg single ascending dose
Number of subjects: 96
Study 33331980 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-025 (ASD-in-Capsule) multiple ascending doses (100, 200, 400 mg, twice daily for 8 days)
Number of subjects: 96
Study 33331980 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-025 (ASD-in-Capsule)
Number of subjects: 96
Study 32488672 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 1 or higher AKI
Number of subjects: 923
Study 32488672 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe AKI (stage 2 or higher)
Number of subjects: 923
Study 32488672 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI stage 1 or higher during early follow-up (days 3-7)
Number of subjects: 923
Study 32488672 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI stage 1 or higher during middle follow-up (days 8-14)
Number of subjects: 923
Study 32488672 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI stage 1 or higher during late follow-up (after day 14)
Number of subjects: 923
Study 32488672 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe AKI rates for 24-week GA group
Number of subjects: 923
Study 32488672 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe AKI rates for 25-week GA group
Number of subjects: 923
Study 32488672 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe AKI rates for 26-week GA group
Number of subjects: 923
Study 32488672 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe AKI rates for 27-week GA group
Number of subjects: 923
Study 35543679 — intervention group
Group type: EXPERIMENTAL
Intervention: SherpaPak controlled cold organ system
Number of subjects: 81
Study 35543679 — intervention group
Group type: COMPARATOR
Intervention: Conventional ice storage technique
Number of subjects: 81
Study 32176882 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk fat globule membrane (MFGM) concentrates
Number of subjects: 0
Study 35085016 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicines (IHMs)
Number of subjects: 60
Study 35085016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32732787 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up telephone call program (n=1534)
Number of subjects: 3054
Study 32732787 — intervention group
Group type: COMPARATOR
Intervention: Usual care discharge (n=1520)
Number of subjects: 3054
Study 36364960 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (1347 individuals)
Number of subjects: 2693
Study 36364960 — intervention group
Group type: COMPARATOR
Intervention: Control group (1346 individuals)
Number of subjects: 2693
Study 33861384 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavioral therapy (CBT) for OCD, 14 weekly sessions
Number of subjects: 269
Study 33861384 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and adolescents with HA symptoms
Number of subjects: 269
Study 33861384 — intervention group
Group type: COMPARATOR
Intervention: Children and adolescents without HA symptoms
Number of subjects: 269
Study 34027716 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week behavioral physical activity intervention
Number of subjects: 32
Study 34027716 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 32
Study 32354152 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g PHGG up to three times per day for 3 weeks
Number of subjects: 20
Study 34420375 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (1 mg/kg for 60 days)
Number of subjects: 21
Study 34420375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 33432496 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain bupivacaine
Number of subjects: 90
Study 33432496 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 90
Study 33432496 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of liposomal bupivacaine and plain bupivacaine
Number of subjects: 90
Study 35183790 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided adaptive radiotherapy combined with hepatic artery chemoembolization
Number of subjects: 84
Study 35183790 — intervention group
Group type: COMPARATOR
Intervention: Hepatic artery chemoembolization
Number of subjects: 84
Study 34851411 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg per day intranasal OP0201 for 10 days
Number of subjects: 103
Study 34851411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 34426106 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg, subcutaneous, once)
Number of subjects: 68
Study 32131881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized iloprost for 5 days
Number of subjects: 150
Study 32131881 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% for 5 days (Control)
Number of subjects: 150
Study 32131881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized iloprost
Number of subjects: 150
Study 35773028 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal nerve blocks (IPACK, triangle femoral and obturator nerve blocks)
Number of subjects: 90
Study 34914294 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Huoxue Decoction (1 dose a day, twice daily for 3 months)
Number of subjects: 60
Study 34914294 — intervention group
Group type: COMPARATOR
Intervention: Shengjing Tablets (4 tablets once, tid) combined with L-carnitine oral solution (10 ml, bid for 3 months)
Number of subjects: 60
Study 36173691 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 90
Study 36173691 — intervention group
Group type: COMPARATOR
Intervention: Control (no analgesia)
Number of subjects: 90
Study 33221093 — intervention group
Group type: EXPERIMENTAL
Intervention: MBS width measurement
Number of subjects: 678
Study 33221093 — intervention group
Group type: EXPERIMENTAL
Intervention: MBS height measurement
Number of subjects: 678
Study 33221093 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of bone width
Number of subjects: 678
Study 33221093 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of bone height
Number of subjects: 678
Study 34740861 — intervention group
Group type: EXPERIMENTAL
Intervention: osimertinib
Number of subjects: 682
Study 34740861 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 682
Study 33662951 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicines (IH) plus psychological counseling (PC)
Number of subjects: 62
Study 33662951 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus psychological counseling (PC)
Number of subjects: 62
Study 32768154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS with 3 mA and low dosage of flunarizine (2.5 mg)
Number of subjects: 12
Study 32768154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS with 3 mA and medium dosage of flunarizine (5 mg)
Number of subjects: 12
Study 32768154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS with 3 mA and high dosage of flunarizine (10 mg)
Number of subjects: 12
Study 34836479 — intervention group
Group type: EXPERIMENTAL
Intervention: At-scale professional development program for math teachers lasting a full school year
Number of subjects: 341
Study 34836479 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 341
Study 34637849 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant fabric warming (RFW)
Number of subjects: 257
Study 34637849 — intervention group
Group type: COMPARATOR
Intervention: Forced-air warming (FAW)
Number of subjects: 257
Study 32539887 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent modelling of fruit and vegetable intake
Number of subjects: 0
Study 32539887 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent modelling of energy dense foods
Number of subjects: 0
Study 32539887 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent sedentary hours
Number of subjects: 0
Study 35285017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping sound intervention (2 × 50-min face-to-face sessions plus follow-up phone call)
Number of subjects: 245
Study 35285017 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 245
Study 35285017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping sound intervention
Number of subjects: 245
Study 32273183 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix
Number of subjects: 103
Study 32273183 — intervention group
Group type: COMPARATOR
Intervention: Degarelix
Number of subjects: 103
Study 35853297 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of docosahexaenoic acid (DHA, 22:6n3)
Number of subjects: 2802
Study 35853297 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA, 18:3n3)
Number of subjects: 2802
Study 35853297 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid (LA, 18:2n6)
Number of subjects: 2802
Study 35853297 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosatetraenoic acid (DTA, 22:4n6)
Number of subjects: 2802
Study 34187460 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-study (G‐SS)
Number of subjects: 51
Study 34187460 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 51
Study 34954406 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil therapy
Number of subjects: 69
Study 34954406 — intervention group
Group type: COMPARATOR
Intervention: Almond oil (placebo)
Number of subjects: 69
Study 34967899 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome suspension block + oral placebo (BUP)
Number of subjects: 30